BIOWAY INC has a total of 24 patent applications. It decreased the IP activity by 88.0%. Its first patent ever was published in 2015. It filed its patents most often in Republic of Korea, United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO LTD, SHANGHAI FOCHON PHARMACEUTICAL CO LTD and 3-V BIOSCIENCES INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Republic of Korea | 7 | |
#2 | United States | 3 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | Australia | 2 | |
#5 | EPO (European Patent Office) | 2 | |
#6 | United Kingdom | 2 | |
#7 | Brazil | 1 | |
#8 | Canada | 1 | |
#9 | China | 1 | |
#10 | Japan | 1 | |
#11 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology | |
#4 | Foods and drinks |
# | Name | Total Patents |
---|---|---|
#1 | Kim Jong Woo | 10 |
#2 | Kim Jong-Woo | 9 |
#3 | Lee Chi Woo | 9 |
#4 | Lee Chi-Woo | 8 |
#5 | Hong Su-Ji | 8 |
#6 | Kim Hak Sung | 5 |
#7 | Kwon Sang Hoon | 5 |
#8 | Joshi Dirgha Raj | 4 |
#9 | Chi-Woo Lee | 3 |
#10 | Hong Suji | 3 |
Publication | Filing date | Title |
---|---|---|
WO2019190177A1 | (2e,4e)-5-phenyl-penta-2,4-dien-1-one derivative | |
KR20180136930A | Novel Quinazolinone derivatives as PI3K inhibitors, and pharmaceutical composition comprising the same | |
KR20180008299A | Novel Quinazolinone derivatives as PI3K inhibitors, and pharmaceutical composition comprising the same | |
KR20180053019A | Cosmetic composition having safety and superior moisturizing effect for skin | |
KR20180053032A | Novel piperidine derivatives and pharmaceutical composition comprising the same | |
KR20170034611A | Adenophora radix extract containing saponin of adenophora radix as bile acid regulator or farnesoid x receptor agonist, and pharmaceutical or food supplement composition for preventing or treating fatty liver disease and primary biliary cirrhosis |